Heska (NASDAQ:HSKA) issued its quarterly earnings results on Wednesday. The medical research company reported $0.63 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.07, Briefing.com reports. The firm had revenue of $36.04 million for the quarter, compared to analyst estimates of $40.56 million. Heska had a return on equity of 15.35% and a net margin of 10.67%. The business’s revenue was down 8.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.46 earnings per share.
Shares of Heska (NASDAQ:HSKA) traded down $1.46 during trading on Wednesday, reaching $59.69. The company had a trading volume of 326,600 shares, compared to its average volume of 101,846. Heska has a 52-week low of $56.59 and a 52-week high of $115.00. The stock has a market capitalization of $442.96, a P/E ratio of 35.36, a price-to-earnings-growth ratio of 1.58 and a beta of 0.67.
A number of analysts have recently issued reports on HSKA shares. Aegis reaffirmed a “buy” rating on shares of Heska in a research note on Tuesday, December 19th. Zacks Investment Research lowered Heska from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Sidoti raised Heska from a “neutral” rating to a “buy” rating and set a $94.00 price target on the stock in a research note on Monday, February 5th. BidaskClub lowered Heska from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Finally, B. Riley set a $93.00 price target on Heska and gave the stock a “hold” rating in a research note on Monday. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $110.08.
Heska Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.